Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours

Bookmark and Share
Published: 11 Apr 2019
Views: 1808
Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Prasad Adusumilli gives a press conference at AACR 2019 on results from a phase I clinical trial showing that CAR T cell therapy, targeting the protein mesothelin, produced anti-tumour activity with no evidence of major toxicity when treating patients with advanced solid tumours.